Sanofi/Regeneron's Dupixent Performance in Eosinophilic Esophagitis is Paving the Way for Future Therapies in an Underserved and Growing Market, According to Spherix Global Insights
EXTON, Pa., April 3, 2023 /PRNewswire/ -- In 2017, Sanofi/Regeneron announced the FDA approval for the first biologic agent to treat atopic dermatitis (AD). The success of that drug, Dupixent (dupilumab), inspired competitors to scramble for a place in the AD market, with the second drug arriving nearly five years later. Sanofi/Regeneron followed with indications in asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (EoE) and most recently prurigo nodularis.
- Sanofi/Regeneron followed with indications in asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (EoE) and most recently prurigo nodularis.
- The May 2022 approval of Dupixent for EoE opened the door to another untapped market, with the closest competitor entry likely several years away.
- Spherix will continue to track the performance of Dupixent's launch for the first eighteen months on the market.
- Performance to date suggests Dupixent will continue to carve out a commanding ownership of the advanced treatment market in EoE, while also paving the way for future competitors to meet the needs of this underserved, growing market.